{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:45:30Z","timestamp":1790635530057,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.euo.2020.11.010","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T17:17:36Z","timestamp":1613927856000},"page":"456-463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial"],"prefix":"10.1016","volume":"4","author":[{"given":"Bernadett","family":"Szabados","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejo","family":"Rodriguez-Vida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Crabb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel S.","family":"Van Der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert Font","family":"Pous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenaelle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urbano Anido","family":"Herranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Protheroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Ravaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Maillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Mendez-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Linch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Prendergast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Tyson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Mousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2020.11.010_bib0005","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ctrv.2017.01.007","article-title":"A review on the evolution of PD-1\/PD-L1 immunotherapy for bladder cancer: The future is now","volume":"54","author":"Bellmunt","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.euo.2020.11.010_bib0010","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2020.11.010_bib0015","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.11.010_bib0020","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.annonc.2020.09.011","article-title":"Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study","volume":"31","author":"Bandini","year":"2020","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.euo.2020.11.010_bib0025","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.euo.2020.11.010_bib0030","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-020-1086-y","article-title":"Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma","volume":"26","author":"Gao","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2020.11.010_bib0035","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.euo.2020.11.010_bib0040","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1200\/JCO.2019.37.15_suppl.4551","article-title":"A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC)","volume":"37","author":"Gao","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.11.010_bib0045","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1158\/1078-0432.CCR-10-0569","article-title":"Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial","volume":"16","author":"Carthon","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2020.11.010_bib0050","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"New Engl J Med"},{"key":"10.1016\/j.euo.2020.11.010_bib0055","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2020.11.010_bib0060","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1200\/JCO.2020.38.15_suppl.5000","article-title":"IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC)","volume":"38","author":"Hussain","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.11.010_bib0065","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(99)02292-8","article-title":"Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party","volume":"354","author":"EORTC Genito-Urinary Group","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2020.11.010_bib0070","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.euf.2017.12.011","article-title":"A simplified frailty index to predict outcomes after radical cystectomy","volume":"5","author":"Sathianathen","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2020.11.010_bib0075","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1200\/jco.2015.33.7_suppl.374","article-title":"Frailty as a marker of adverse outcomes during cystectomy for urothelial cancer","volume":"33","author":"Kates","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.11.010_bib0080","doi-asserted-by":"crossref","first-page":"399","DOI":"10.17219\/acem\/115085","article-title":"Geriatric assessment among elderly patients undergoing urological surgery: a systematic literature review","volume":"29","author":"Michalik","year":"2020","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.euo.2020.11.010_bib0085","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With Cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.11.010_bib0090","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1080\/00140130500101247","article-title":"Ageing and activity: their effects on the functional reserve capacities of the heart and vascular smooth and skeletal muscles","volume":"48","author":"Goldspink","year":"2005","journal-title":"Ergonomics"},{"key":"10.1016\/j.euo.2020.11.010_bib0095","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.euo.2018.05.010","article-title":"Staging the host: personalizing risk assessment for radical cystectomy patients","volume":"1","author":"Psutka","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2020.11.010_bib0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.e16524","article-title":"A pilot pre-surgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients with muscle-Invasive, high-risk urothelial bladder carcinoma who are ineligible for cisplatin-based neoadjuvant chemotherapy","volume":"36","author":"Gao","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.11.010_bib0105","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1200\/JCO.2020.38.15_suppl.5012","article-title":"DUTRENEO trial: a randomized phase II trial of durvalumab and tremelimumab versus chemotherapy as a neoadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature","volume":"38","author":"Grande","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.11.010_bib0110","doi-asserted-by":"crossref","first-page":"viii726","DOI":"10.1093\/annonc\/mdy424.039","article-title":"A phase Ib\/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC)","volume":"29","author":"Hoimes","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2020.11.010_bib0115","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1200\/JCO.2020.38.6_suppl.439","article-title":"Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.11.010_bib0120","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00345-018-2584-0","article-title":"Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy","volume":"37","author":"Milenkovic","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2020.11.010_bib0125","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","volume":"77","author":"Necchi","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.11.010_bib0130","doi-asserted-by":"crossref","first-page":"TPS4592","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4592","volume":"37","author":"Powles","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.11.010_bib0135","doi-asserted-by":"crossref","first-page":"TPS599","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS599","article-title":"Phase III study of perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) versus placebo plus neoadjuvant chemo in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-866","volume":"38","author":"Siefker-Radtke","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.11.010_bib0140","doi-asserted-by":"crossref","first-page":"TPS4587","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4587","article-title":"A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) \u00b1 BMS-986205 in cisplatin-eligible muscle invasive bladder cancer (MIBC)","volume":"37","author":"Sonpavde","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931120302066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931120302066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:46:20Z","timestamp":1762875980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931120302066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2588931120302066"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2020.11.010","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2020.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}